Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 Monotherapy in HER2+ Advanced Breast and Gastric Cancer
NCT03619681Phase 1Completed
- Sponsor
- Alphamab Oncology
- Start
- Sep 2018
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anbenitamab in breast cancer and gastric cancer (GC), sponsored by Alphamab Oncology. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Sep 2018; status: completed.
02
Drugs
anbenitamab
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03619681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619681.